Oral Semaglutide Reduces Heart Disease Risk Even When Combined with SGLT2 Inhibitors
Major diabetes trial shows GLP-1 drugs maintain cardiovascular benefits when used alongside SGLT2 inhibitors, supporting combination therapy.
Summary
The SOUL trial analyzed 9,650 people with type 2 diabetes and cardiovascular disease, finding that oral semaglutide reduced major heart events by 14% overall. Importantly, the drug maintained its protective effects whether patients were also taking SGLT2 inhibitors or not, with no safety concerns from combining these medications. This supports using both drug classes together for maximum cardiovascular protection.
Detailed Summary
This landmark analysis from the SOUL trial provides crucial evidence for combining two major diabetes drug classes to protect against heart disease. Researchers studied 9,650 people with type 2 diabetes and existing cardiovascular or kidney disease over nearly four years.
The study found that oral semaglutide reduced major cardiovascular events (heart attack, stroke, or cardiovascular death) by 14% compared to placebo. Critically, this benefit remained consistent whether patients were also taking SGLT2 inhibitors like empagliflozin or not - addressing a key clinical question about combining these therapies.
Among the 2,596 participants using SGLT2 inhibitors at baseline, semaglutide showed similar protective effects as in those not using these drugs. The combination appeared safe, with no increased adverse events when both drug classes were used together.
These findings have major clinical implications. Both GLP-1 receptor agonists and SGLT2 inhibitors are recommended by guidelines for people with diabetes and cardiovascular disease, but evidence supporting their combined use was limited. This analysis provides the largest dataset to date on combination therapy, giving clinicians confidence to prescribe both medications together.
The results suggest these drugs work through different biological pathways, making their benefits potentially additive rather than redundant. This supports current treatment guidelines recommending both drug classes for high-risk diabetes patients, regardless of blood sugar control needs.
Key Findings
- Oral semaglutide reduced major cardiovascular events by 14% regardless of SGLT2 inhibitor use
- No safety concerns emerged from combining GLP-1 and SGLT2 inhibitor therapies
- Benefits remained consistent across 2,596 patients using SGLT2 inhibitors at baseline
- Largest dataset to date supporting combination therapy for cardiovascular protection
Methodology
Double-blind, placebo-controlled trial with 9,650 participants across 33 countries, followed for mean 47.5 months. Prespecified analysis stratified by baseline and any SGLT2 inhibitor use during the trial.
Study Limitations
Observational analysis within a randomized trial. SGLT2 inhibitor use was not randomized. Results may not apply to all GLP-1 receptor agonists or patient populations outside the study criteria.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.